Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii crawled date : 2021 - 11 - 15 save search
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published: 2021-11-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ARWR | $23.94 7.21% 6.73% 1.1M
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
phase 2 hepatitis phase 2b injection infections chronic hepatitis b
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Published: 2021-11-15 (Crawled : 17:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 1.63%
H: 0.43%
C: -0.3%
phase 2
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
IFRX | $1.39 2.96% 2.88% 120K
|
Health Technology
|
| O: -1.97%
H: 3.94%
C: -10.42%
positive
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency- Preliminary biomarker and safety data expected in the first half of 2022 -
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
INZY | $4.39 -2.66% -2.73% 810K
|
Health Technology
|
| O: 0.6%
H: 1.39%
C: -0.5%
trial biomarkers
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
IMMP | $2.33 3.56% 3.43% 170K
|
Health Technology
|
| O: 0.47%
H: 1.16%
C: -0.93%
positive therapy trial
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
RDHL | $0.44 -2.66% -2.73% 83K
|
Health Technology
|
| O: -2.83%
H: 0.0%
C: 0.0%
covid phase 2 biopharma ongoing phase 2/3
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery
Published: 2021-11-15 (Crawled : 14:00) - biospace.com/
MRNA | News S | $104.48 3.03% 2.94% 3.1M
|
Health Technology
|
| O: 2.19%
H: 0.0%
C: 0.0%
phase 2 positive
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
NVCR | $11.82 -2.23% -2.28% 810K
|
Health Technology
|
| O: 3.0%
H: 0.39%
C: -3.17%
phase 2 positive results trial topline glioblastoma
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
ARWR | $23.94 7.21% 6.73% 1.1M
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.